Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Amneal Pharmaceuticals Q3 2026 Results: Net Loss of $21.7M

Amneal Pharmaceuticals reported net revenue of $862.7 million for the third quarter of 2026, an increase from $784.5 million in the prior year period. Despite higher operating income, the company recorded a net loss attributable to Class A common stockholders of $21.7 million for the quarter, primarily due to accretion of redeemable non-controlling interests and acquisition-related costs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue862.7784.5
Gross profit334.1274.0
Profit before tax15.1-5.2
Net income-21.72.4
EPS (diluted, $ a share)$-0.06$0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+10.0%
Gross margin38.7%
Operating margin11.1%
Source

10-Q filed with the SEC, NASDAQ: AMRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Amneal Pharmaceuticals, Inc.: key numbers

Share price
$21.12Close, Nov 17
Market cap
$7.36B
Shares outstanding
348.41MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Amneal Pharmaceuticals, Inc.

All →
8:08 AM ET 8-K
Financial Results

Amneal Pharmaceuticals Financial Results

Amneal Pharmaceuticals reported Q3 2026 net revenue of $863 million, a 10% increase year-over-year, driven by strong growth in biosimilars and specialty products. Despite the revenue growth, the company posted a GAAP net loss of $22 million due to acquisition and integration costs related to Kashiv. Consequently, Amneal raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS.

Term
Q3 2026

“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT®, and BREKIYA® autoinjector.”

Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers
4:06 PM ET 8-K/A
M&A Deal

Amneal Pharmaceuticals M&A Deal with Kashiv BioSciences, LLC

Amneal Pharmaceuticals filed an amendment to its previous 8-K to provide required historical financial statements and pro forma financial information following its completed acquisition of Kashiv BioSciences, LLC. The acquisition was originally completed on August 10, 2026, pursuant to a Membership Interest Purchase Agreement dated April 21, 2026.

Counterparty
Kashiv BioSciences, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.